Argenx's VYVDURA approved in Japan for CIDP, making it first FcRn blocker approved

From Nasdaq: 2024-12-27 01:21:37

Japan’s Ministry of Health, Labour and Welfare approved VYVDURA by argenx SE for adults with chronic inflammatory demyelinating polyneuropathy. The once-weekly 30-to-90 second subcutaneous injection can be self-administered at home and is the first FcRn blocker approved for CIDP. CIDP is a rare neuromuscular disorder causing mobility and sensory issues. VYVDURA is now approved in Japan for at-home self-injection for both myasthenia gravis and CIDP. argenx’s VYVGART and VYVDURA portfolio is approved in Japan for three indications, making it the first country globally with access to all three.



Read more at Nasdaq: Argenx’s VYVDURA Approved In Japan For Chronic Inflammatory Demyelinating Polyneuropathy